Improved clinical parameters of Tau.P301L mice vaccinated with ACI-35.
Clara Theunis
Natalia Crespo-Biel
Valérie Gafner
Maria Pihlgren
María Pilar López-Deber
Pedro Reis
David T. Hickman
Oskar Adolfsson
Nathalie Chuard
Dorin Mlaki Ndao
Peter Borghgraef
Herman Devijver
Fred Van Leuven
Andrea Pfeifer
Andreas Muhs
10.1371/journal.pone.0072301.g004
https://plos.figshare.com/articles/figure/_Improved_clinical_parameters_of_Tau_P301L_mice_vaccinated_with_ACI_35_/776851
<p>(A) The left panel shows the evolution of the bodyweight of Tau.P301L mice over 3 months of ACI-35 vaccination relative to PBS injected Tau.P301L mice. The panel on the right presents the loss in bodyweight of the Tau.P301L mice at day 91 relative to the start of the study (day -7). Data: mean± SEM (p = 0.094, unpaired Student's t-test). (B) Clasping score of vaccinated Tau.P301L mice compared to placebo injected Tau.P301L mice. (C) Rotarod performance of ACI-35 vaccinated Tau.P301L mice compared to PBS-injected Tau.P301L mice, tested over 300 sec on the accelerating rod (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072301#s2" target="_blank">Methods</a> section for details). Data: mean± SEM. (E) Mortality of Tau.P301L mice vaccinated with ACI-35 versus placebo Tau.P301L mice.</p>
2013-08-19 05:08:48
immunology
immunity
immunizations
immunotherapy
Model organisms
Animal models
mouse
Clinical immunology
vaccination
vaccines
Vaccine development
Clinical research design
Preclinical models
neurology
dementia
Alzheimer disease
Neurodegenerative diseases
mice
vaccinated